Allergy-relieving Eye Drops Market – Snapshot
The global allergy-relieving eye drops market is expected to reach a value of US$ 1,930.3 Mn by the end of 2026, expanding at a significant CAGR of 5.0% during the forecast period. Increase in prevalence and incidence rates of eye-related disorders, high unmet needs in patients with ocular allergy, increased geriatric population, raised awareness about eye diseases in developing countries are expected to boost the allergy-relieving eye drops market during the forecast period.
Moreover, significant rise in incidence of eye-related diseases, especially in developed countries, is anticipated to drive the allergy-relieving eye drops market between 2018 and 2026. According to the Prevent Blindness Report, the number of people in the U.S. suffering from cataract is expected to increase from 24.4 Mn in 2010, to 30.5 Mn by 2020, and the number of people suffering from diabetic retinopathy in the U.S. is projected to rise from 7.7 Mn in 2010 to reach 9.2 Mn by 2020
The global allergy-relieving eye drops market has been segmented based on drug class, type, distribution channel, and region. In terms of drug class, the global market has been classified into antihistamines, non-steroidal anti-inflammatory drugs, vasoconstrictors, and others. The antihistamines segment dominates the allergy-relieving eye drops market, in terms of value. The wide acceptance of antihistamines as the first line of treatment for allergic conjunctivitis is likely to drive the segment. Furthermore, increase in the prevalence of allergic conjunctivitis and rise in awareness about eye-related disorders are anticipated to propel the segment during the forecast period. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of ocular allergy. The vasoconstrictors segment follows the antihistamines segment, in terms of share, of the global allergy-relieving eye drops market. The dominance of the segment is attributed to the extensive utilization of vasoconstrictors to relieve redness of the eyes associated with ocular allergy.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14933
In terms of type, the global market has been classified into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis, and others. The seasonal and perennial allergic conjunctivitis segment is likely to dominate the global allergy-relieving eye drops market during the forecast period.
In terms of distribution channel, the allergy-relieving eye drops market has been segregated into hospital pharmacies, retail, and online sales. The retail segment held a major share of the market in 2017, followed by hospital pharmacies. The retail segment is expected to maintain its market share during forecast period due to the availability of both prescription as well as OTC drugs for allergic conjunctivitis. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for certain form of ocular allergies.
In terms of region, the allergy-relieving eye drops market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the allergy-relieving eye drops market, owing to the high awareness about minor eye-related disorders in the U.S. and increased prevalence of allergic conjunctivitis in the region. Moreover, North America is anticipated to be a highly attractive market for allergy-relieving eye drops during the forecast period, owing to the high cost of prescription drugs and a significant number of people in this region covered by medical insurance.
Request a Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14933
Major players operating in the allergy-relieving eye drops market include Allergan Plc., Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical companies, which is expected to increase the product availability and thereby boost the market.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
This post was originally published on The Market Plan